1 active not recruiting, 1 terminated, 1 unknown. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Active not recruiting 1, Unknown 1 |
Follow Neoplasm of Bone: new trials by email Literature Review of Neoplasm of Bone trials Research Report on Neoplasm of Bone
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 9-ING-41 in Patients With Advanced Cancers 9-ING-41, Gemcitabine - 21 day cycle, Doxorubicin. - Cancer, Pancreatic Cancer | Phase 2 | Active not recruiting | Actuate Therapeutics Inc. | 350 | 2019-01-04 | 2026-04-03 |
| Study of Anlotinib in Patients With Primary Malignant Bone Tumors Anlotinib - Neoplasm of Bone | Phase 2 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 40 | 2018-01-31 | 2019-05-21 |
| National Swiss Sarcoma Cohort Study Registration - Sarcoma, Neoplasm of Bone | Terminated | Balgrist University Hospital | 50 | 2015-04-01 | 2018-10-02 |
Bone Neoplasms (3) · Neoplasms (2) · Sarcoma (2) · Breast Neoplasms (1) · Colorectal Neoplasms (1) · Glioma (1) · Hereditary Sensory and Autonomic Neuropathies (1) · Kidney Neoplasms (1) · Leukemia-Lymphoma, Adult T-Cell (1) · Lung Neoplasms (1) · Lymphoma, Non-Hodgkin (1) · Neoplasm Metastasis (1) · Osteosarcoma (1) · Pancreatic Neoplasms (1) · Soft Tissue Neoplasms (1)
Bone Diseases (3) · Musculoskeletal Diseases (3) · Neoplasms by Site (3) · Neoplasms by Histologic Type (2) · Neoplasms, Connective and Soft Tissue (2) · Breast Diseases (1) · Colonic Diseases (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Endocrine Gland Neoplasms (1) · Endocrine System Diseases (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Doxorubicin (1) · Gemcitabine (1) · Irinotecan (1) · Lomustine (1) · Paclitaxel (1) · Taxes (1) · anlotinib (1) · liposomal doxorubicin (1)
Actuate Therapeutics Inc. (1) · Balgrist University Hospital (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1)
Belgium (1) · Canada (1) · China (1) · France (1) · Netherlands (1) · Portugal (1) · Spain (1) · Switzerland (1) · United States (1)
Bruno Fuchs, MD PhD (1) · Yang Yao (1)
PMID 24327518, PMID 27424289, PMID 28053024, PMID 28672195, PMID 29383130, PMID 29846250, PMID 30405781, PMID 30975030, PMID 31101621, PMID 31401903, PMID 31533931, PMID 31831767, PMID 31882719, PMID 31894292, PMID 35815408, PMID 41981308